section name header

Pronunciation

kas-po-FUN-gin

Classifications

Therapeutic Classification: antifungals

Pharmacologic Classification: echinocandins

Indications

REMS


Action

  • Inhibits the synthesis of β (1, 3)-D-glucan, a necessary component of the fungal cell wall.
Therapeutic effects:
  • Death of susceptible fungi.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Widely distributed to tissues.

Protein Binding: 97%.

Metabolism/Excretion: Slowly and extensively metabolized; <1.5% excreted unchanged in urine.

Half-Life: Polyphasic: βphase: 9–11 hr; γphase: 40–50 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
IVunknownend of infusion24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: flushing, pruritus, rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS

GI: liver enzymes, diarrhea, nausea, vomiting

GU: serum creatinine

Local: venous irritation at injection site

Neuro: headache

Resp: bronchospasm

Misc: chills, fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)

Interactions

Drug-drug:

Route/Dosage

Hepatic Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Cancidas